Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ IGFBP2 Monoclonal Antibody (1F6F6)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA515400
Description
MA5-15400 targets IGFBP2 in indirect ELISA, IHC and WB applications and shows reactivity with Human samples. The MA5-15400 immunogen is purified recombinant fragment of protein IGFBP2 (aa180-328) expressed in E. Coli. .
IGFBP2 (insulin-like growth factor binding protein 2) is a member of the ISGBP family which bind various IGFs. IGFBP2 is overexpressed in a wide spectrum of cancers, including glioma, prostate cancer, synovial sarcoma, neuroblastoma, colon cancer, adrenocortical cancer, lung cancer, Wilms' tumor, and hepatoblastoma. The overexpression of IGFBP2 also correlates with the aggressiveness of some tumors. IGFBP2 activates the expression of matrix metalloprotease 2, which contributes to cell invasiveness.
Specifications
IGFBP2 | |
Monoclonal | |
Conc. Not Determined | |
Ascites with 0.03% sodium azide | |
P18065 | |
IGFBP2 | |
Purified recombinant fragment of protein IGFBP2 (aa180-328) expressed in E. Coli. | |
RUO | |
3485 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
ELISA, Immunohistochemistry (Paraffin), Western Blot | |
1F6F6 | |
Unconjugated | |
IGFBP2 | |
AI255832; BP2; BRL-BP; IBP2; IBP-2; IGF binding protein 2; IGF-binding protein 2; IGFBP; IGFBP2; IGFBP-2; IGF-BP53; ILGFBPA; Insulin like growth factor binding protein; insulin like growth factor binding protein 2; insulin-like growth factor binding protein 2; insulin-like growth factor binding protein 2, 36kDa; insulin-like growth factor-binding protein 2; mIGFBP-2; OTTHUMP00000207753 | |
Mouse | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction